S&P 500 Healthcare Sector SEC Filings — April 16, 2026

16-04-2026

First Business Financial Services, Inc. appointed David R. Seiler, current President and COO since January 2023, as President, Chief Executive Officer, and Class III Director effective May 3, 2026, succeeding retiring CEO Corey A. Chambas whose retirement was announced in May 2025. The appointment coincides with a new five-year employment agreement providing a minimum annual base salary of $600,000, eligibility for incentive plans, and a $215,000 restricted stock unit grant vesting over five years. The agreement includes standard severance provisions, such as two times base salary upon termination without cause, and customary restrictive covenants.

• ·Employment agreement effective May 3, 2026, with initial 5-year term and automatic 1-year renewals unless 60 days' notice
• ·RSU vesting schedule: 15% on each of first four anniversaries, 40% on fifth anniversary, subject to continued employment
• ·Severance for termination without Cause or for Good Reason: 2x then-current base salary over 24 months, prorated incentive, 18 months health coverage
• ·Mr. Seiler has over 30 years of financial services experience; prior Managing Director at BMO Harris Bank
• ·Appointment to Board as Class III Director until 2028 Annual Meeting

16-04-2026

DISCIPLINED GROWTH ACQUISITION Corp, a blank check company, filed an S-1 registration statement on April 16, 2026, exempt from SEC Rule 419, allowing immediately tradable units and extended time for initial business combination. Key risks include only $1,000,000 available outside the trust account for operations, estimated offering expenses of $650,000, up to $1,500,000 in potential convertible loans from sponsor at $10.00 per unit, and restrictions on redeeming more than 15% of Class A ordinary shares per shareholder/group. Additional concerns involve intense competition for targets, limited resources, and potential reduction of trust account below $10.00 per share due to third-party claims despite sponsor indemnification.

• ·Sponsor liable for third-party claims reducing trust below $10.00 per share (except auditors and waived claims), but no reserved funds verified
• ·Independent directors may not enforce sponsor indemnification if costs too high
• ·Claims against trust account possible within 10 years post-redemption
• ·Prior to business combination, loans sought only from sponsor or affiliates

16-04-2026

On April 14, 2026, Michael L. Swenson, a member of the Board of Directors of Citizens Community Bancorp, Inc. (CZWI) since May 2011, provided notice that he will continue serving until the 2026 annual meeting of stockholders on June 16, 2026, but does not plan to stand for re-election. Mr. Swenson's decision is not due to any disagreement with the Company. The filing was signed by James S. Broucek, Chief Financial Officer, on April 16, 2026.

• ·Company incorporated in Maryland; NASDAQ: CZWI; Principal offices in Eau Claire, WI.

16-04-2026

Invesco Commercial Real Estate Finance Trust, Inc. reported total net asset value (NAV) of $1,210,172 thousand as of March 31, 2026, with NAV per share ranging from $24.8460 (Class D) to $25.9583 (Class F) across share classes. The commercial real estate loan portfolio had a fair value and outstanding principal balance of $5.2 billion, reflecting stability with no noted declines. In March 2026, the company closed three loan originations totaling $296.5 million and received repayments on two loans totaling $84.4 million.

• ·Transactions or events have occurred since March 31, 2026 that could materially impact NAV per share.
• ·NAV per share by class: Class S $24.8694, Class S-1 $24.9794, Class D $24.8460, Class D-1 $24.8796, Class I $24.9424, Class E $25.8327, Class F $25.9583.
• ·Secured financing facilities fair value: $(3,044,335) thousand.
• ·Collateralized loan obligations fair value: $(1,004,858) thousand.
• ·$4.0 billion of loans held outside of the CLO and $80.7 million of loans held by the consolidated CLO; $1.1 billion CLO loans valued using observable fair value of CLO notes.

16-04-2026

First Financial Bancorp's DEF 14A Proxy Statement for the May 26, 2026 virtual Annual Meeting seeks shareholder approval for electing 10 directors, ratifying Crowe LLP as 2026 independent auditors, approving the 2026 Stock Plan, and an advisory vote on executive compensation; record date is March 27, 2026. The company reports strong 2025 performance with record revenue and noninterest income, completion of Westfield Bank acquisition adding 8 financial centers in northeast Ohio, and an agreement to acquire BankFinancial Corporation. Community initiatives included $4.6 million in grants/donations and over 16,300 associate volunteer hours, with no material declines noted.

• ·Annual Meeting at 10:00 AM Eastern Time on May 26, 2026, virtually at virtualshareholdermeeting.com/FFBC2026
• ·Shareholders of record as of March 27, 2026 eligible to vote
• ·5-star rating from Bauer Financial; Investment Grade rating from Kroll Bond Rating Agency
• ·Received Gallup Exceptional Workplace Award and second consecutive Outstanding CRA rating from Federal Reserve Board

16-04-2026

News Corporation disclosed details on its ongoing $1 billion stock repurchase program for Class A (NWSA) and Class B (NWS) common stock, including daily transaction disclosures to the Australian Securities Exchange (ASX) as required. Exhibits 99.1 and 99.2 contain the specific information provided to the ASX on respective dates. The filing includes forward-looking statements on potential repurchases, subject to market conditions and other factors.

• ·Date of earliest event reported: April 15, 2026
• ·Filing date: April 16, 2026
• ·Securities: Class A Common Stock (NWSA) and Class B Common Stock (NWS) on Nasdaq Global Select Market

16-04-2026

On April 15, 2026, the Board of Trustees of abrdn National Municipal Income Fund (VFL) approved a change to its non-fundamental investment policy, raising the limit on below-investment grade municipal obligations from 20% of net assets to 100% of assets, effective June 1, 2026, with anticipated initial allocation of 30% rising to 30-50% over time. While this may allow for greater exposure to potentially higher-yielding securities, it increases credit risk, volatility, illiquidity, and substantial risk of loss from speculative high-yield 'junk' bonds. All other investment limitations remain unchanged.

• ·Press release attached as Exhibit 99.1.
• ·Fund's securities trade under symbol VFL on the New York Stock Exchange.

16-04-2026

Corebridge Financial, Inc. estimates preliminary variable investment income of $15 million to $25 million (pre-tax) for the quarter ended March 31, 2026, with positive alternative investment returns offset by unrealized mark-to-market losses on fair value investments. The company is exploring repurchases of its common stock (CRBG) prior to closing its pending merger with Equitable Holdings, Inc. (announced March 26, 2026), which would require a waiver from the merger agreement prohibiting such actions. Full Q1 earnings release is scheduled for May 4, 2026, followed by an earnings call on May 5, 2026.

• ·Preliminary information is unaudited and based on incomplete financial closing procedures; actual results may differ.
• ·Information under Items 2.02 and 7.01 is furnished, not filed, and not incorporated by reference.

16-04-2026

Catalyst Crew Technologies Corp. (CCTC) reported a sharply reduced net loss of $207,485 for the year ended December 31, 2025, compared to $3,261,038 in 2024, primarily due to operating expenses dropping 95% to $171,852 from $3,297,858. However, revenue remained at $0 for both years, total liabilities increased 10% to $630,860 from $573,575, and the company continued to hold zero cash and total assets. Stockholders' deficit widened to match liabilities at $630,860.

• ·Common shares outstanding increased to 44,296,895 from 29,276,895, including 15,020,000 shares issued for cash raising $150,200.
• ·Cash and total assets remained at $0 as of December 31, 2025 and 2024.
• ·Net loss per common share improved to $(0.01) from $(0.11).
• ·Deferred income tax assets of $6,216,165 fully offset by valuation allowance as of Dec 31, 2025.

16-04-2026

Coca-Cola Europacific Partners plc (CCEP) issued a release on April 16, 2026, announcing the availability of proxy materials for its 2026 Annual General Meeting (AGM) scheduled for May 28, 2026, including the Notice of AGM, Form of Proxy, and Amended Long Term Incentive Plan Rules, filed as Exhibits 99.1, 99.2, 99.3, and 4.1. The company operates across 31 countries, serving nearly 600 million consumers and over 4 million customers. No financial performance metrics or period comparisons were disclosed in the filing.

• ·CCEP listed on Euronext Amsterdam, NASDAQ, London Stock Exchange, and Spanish Stock Exchanges; constituent of NASDAQ 100 and FTSE 100 indices; trading symbol CCEP (ISIN GB00BDCPN049).
• ·Principal executive offices: Pemberton House, Bakers Road, Uxbridge, UB8 1EZ, United Kingdom.
• ·Contact emails: svetlana.walker@ccep.com, sarah.willett@ccep.com, mediaenquiries@ccep.com.

16-04-2026

Citizens Financial Group reported first quarter 2026 net income of $517 million, up 39% YoY from $373 million, with diluted EPS of $1.13, up 47% YoY, and positive operating leverage of 7.2% YoY. Total revenue rose 12% YoY to $2,168 million, driven by 12% NII growth to $1,562 million and NIM expansion of 24 bps to 3.14%, while loans grew 1% QoQ and 4% YoY to $143.7 billion and deposits increased 1% QoQ to $184.0 billion. However, pre-provision net revenue declined 3% QoQ to $790 million, noninterest income fell 2% QoQ, noninterest expense rose 3% QoQ and 5% YoY, and net income dipped 2% QoQ.

• ·Board declared quarterly dividend of $0.46 per share, payable May 14, 2026 to shareholders of record April 30, 2026.
• ·CET1 ratio of 10.5%; ROTCE of 12.2%; Efficiency ratio of 63.6%.
• ·Net charge-offs of 39 bps, down 4 bps QoQ and 19 bps YoY; ACL coverage 1.52%.
• ·Private Bank contributed $0.11 to EPS.

16-04-2026

KeyCorp reported Q1 2026 net income of $486 million, up 31% YoY from $370 million, with revenue of $1.95 billion increasing 10% YoY driven by 11% YoY growth in net interest income to $1.23 billion; however, total revenue declined 2.6% QoQ, noninterest income fell 7.5% QoQ, and average consumer loans decreased 7.2% YoY. Period-end loans rose $2.6 billion QoQ with commercial loans up 4%, credit quality remained strong with net charge-offs at 38 bps, and the company repurchased $389 million in common shares, though CET1 ratio dipped to 11.4%. Return on tangible common equity improved to 13.02%, exceeding 13% target progress.

• ·Commercial mortgage servicing fees declined 18.4% YoY to $62M.
• ·Personnel expense increased 9.3% YoY to $743M.
• ·Nonperforming assets at 63 bps of period-end loans plus OREO.
• ·Provision for credit losses $106M, down 10.2% YoY.

16-04-2026

BNY reported record Q1 2026 total revenue of $5.4 billion, up 13% YoY and 4% QoQ, driven by 11% YoY fee revenue growth and 18% YoY net interest income increase, with diluted EPS rising 42% YoY to $2.24 and ROTCE at 29%. However, AUM declined 2% QoQ to $2.1 trillion amid net outflows, Investment and Wealth Management segment revenue fell 3% QoQ, and Issuer Services revenue dropped 16% QoQ. Noninterest expense rose 5% YoY to $3.4 billion, though pre-tax operating margin expanded to 37%.

• ·Average liquidity coverage ratio (LCR) of 111%; Average net stable funding ratio (NSFR) of 131%.
• ·Tier 1 leverage ratio of 6.0%; CET1 ratio of 11.0%.
• ·Securities Services AUC/A of $42.7T (flat QoQ, up 13% YoY).
• ·Market and Wealth Services AUC/A of $16.5T (up 2% QoQ, 11% YoY).
• ·Provision for credit losses benefit of $7M in Q1 2026.

16-04-2026

Abbott reported first-quarter 2026 net sales of $11,164 million, up 7.8% reported and 3.7% comparable YoY, driven by Medical Devices (+8.5% comparable) and Established Pharmaceuticals (+9.0% comparable), while Nutrition declined 7.7% comparable and Diagnostics grew modestly at 1.8% comparable amid weaker respiratory demand. Adjusted diluted EPS increased 6% to $1.15, and the company completed its acquisition of Exact Sciences on March 23, 2026, establishing leadership in oncology diagnostics but including $0.20 dilution in full-year guidance of 6.5%-7.5% comparable sales growth and $5.38-$5.58 adjusted EPS. CEO Robert B. Ford noted alignment with expectations and confidence in accelerating growth.

• ·U.S. Nutrition sales declined 11.6% YoY; Pediatric Nutrition down 13.0% U.S.
• ·Rapid/Molecular Diagnostics down 9.6% comparable YoY due to weaker respiratory virus season.
• ·Quarterly dividend of $0.63 per share declared, payable May 15, 2026.
• ·GAAP diluted EPS $0.61, down from $0.76 YoY.

16-04-2026

Klaas Financial Asset Advisors, LLC filed its 13F-HR on April 16, 2026, reporting total holdings of $724246699 across 59 ETF positions as of March 31, 2026, all with sole voting power and no shared voting or other rights. Largest positions include State Street S&P 500 ETF at $189404506, Dimensional International Core Equity ETF at $89813826, and iShares Mortgage-Backed Securities ETF at $64051941, reflecting a diversified portfolio in equities, treasuries, bonds, and ESG-focused ETFs. No period-over-period changes or performance metrics disclosed.

• ·Central Index Key: 0001819279
• ·SEC File Number: 028-20565
• ·Business Address: 4707 Perry Ridge Lane, Loves Park, IL 61111

16-04-2026

Fiduciary Advisors, Inc. filed its 13F-HR report on April 16, 2026, disclosing sole discretionary holdings in 121 securities valued at $133,089,190 as of March 31, 2026. The portfolio is dominated by ETFs such as iShares Core S&P Mid-Cap ETF (14,437 shares), iShares Core S&P Small-Cap ETF (14,437 shares), and Vanguard Index Funds Mid Cap ETF (29,462 shares), with notable individual stock positions including Bank of America Corp (22,826 shares), US Bancorp (15,559 shares), and NVIDIA Corporation (857 shares). No prior period comparisons, options, or other manager holdings were reported.

• ·Report period end: March 31, 2026
• ·Filing CIK: 0002047030
• ·Business address: 12813 Flushing Meadows Dr, St. Louis, MO 63131
• ·Contact phone: 314-446-0899

16-04-2026

GM Financial Consumer Automobile Receivables Trust 2026-2, a newly formed issuing entity, closed the issuance of $1,269,810,000 in asset-backed notes on April 15, 2026, secured by prime consumer automobile loan contracts (Receivables). The notes comprise Class A-1 ($218,350,000 at 3.826%), Class A-2-A ($375,400,000 at 4.05%), Class A-2-B ($100,000,000 floating rate), Class A-3 ($475,400,000 at 4.15%), Class A-4 ($60,170,000 at 4.22%), Class B ($20,900,000 at 4.44%), and Class C ($19,590,000 at 4.64%). The transaction involves AFS SenSub Corp. as depositor, AmeriCredit Financial Services, Inc. d/b/a GM Financial as sponsor and servicer, with underwriting led by J.P. Morgan Securities LLC.

• ·Closing Date: April 15, 2026
• ·Underwriting Agreement dated April 8, 2026
• ·Trust Agreement originally dated February 27, 2026, amended and restated April 15, 2026
• ·Indenture, Sale and Servicing Agreement, and Purchase Agreement all dated April 15, 2026
• ·GM Financial serves as Servicer and Custodian
• ·Clayton Fixed Income Services LLC as Asset Representations Reviewer

16-04-2026

On April 16, 2026, New York REIT Liquidating LLC, formed to complete the liquidation of assets previously held by New York REIT, Inc., announced a cash liquidating distribution of $0.15 per unit. The distribution will be paid on April 27, 2026, to unitholders of record as of April 17, 2026. No other financial metrics or comparisons were reported.

• ·Filed under Item 8.01 Other Events.
• ·Registrant details: Delaware incorporation, Commission File Number 001-36416, IRS Employer Identification No. 83-2426528, principal offices at 2 Liberty Square, Boston, Massachusetts 02109.

16-04-2026

Ironwood Financial, LLC filed its 13F-HR on April 16, 2026, reporting 168 equity holdings as of March 31, 2026, with a total market value of $572714292. The portfolio is diversified across ETFs and individual stocks, with top holdings including iShares Core S&P 500 ETF valued at $69235225 (105992 shares) and Apple Inc. valued at $38220367 (150598 shares). All positions are held with sole investment discretion and voting power.

• ·All holdings reported as SH (shares) with SOLE discretion
• ·No put/call options or short positions disclosed
• ·Firm address: 1926 E FT. LOWELL ROAD STE 100, TUCSON AZ 85719

16-04-2026

Evofem Biosciences, Inc. entered into a Fourth Amendment to its Securities Purchase Agreement, originally dated October 14, 2020, with Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. on April 10, 2026. The amendment sets the maturity date for the convertible promissory notes to the earlier of six months after the effective date, a Change of Control, or any acceleration event, with no prepayment allowed in the first six months without Adjuvant's consent. No specific financial amounts or performance metrics were disclosed.

• ·Original Securities Purchase Agreement dated October 14, 2020
• ·Amendment filed as Exhibit 10.1
• ·Company address: 7770 Regents Road, Suite 113-618, San Diego, California 92122
• ·Registrant is not an emerging growth company

16-04-2026

New ERA Energy & Digital, Inc. held its 2026 Special Meeting of Stockholders on April 16, 2026, with 23,795,652 shares of common stock present or by proxy, representing 42.06% of the 56,575,187 outstanding shares as of the March 3, 2026 record date. Shareholders overwhelmingly approved Proposal One to authorize the issuance of shares in excess of the Share Cap pursuant to the January 16, 2026 Membership Interest Purchase Agreement with SharonAI, Inc., for Nasdaq compliance, receiving 23,171,142 votes for, 492,261 against, and 132,249 abstentions. Proposal Two to allow adjournment if needed also passed strongly with 22,967,722 votes for.

• ·Proxy statement filed with SEC on March 16, 2026, supplemented on April 10, 2026.
• ·Record date for voting: March 3, 2026.
• ·No broker non-votes for either proposal.

16-04-2026

ENB Financial Corp declared a $0.18 per share 2nd quarter cash dividend on April 15, 2026, payable on June 15, 2026, to shareholders of record on May 15, 2026. The announcement was made via a press release attached as Exhibit 99.

• ·Filing signed on April 16, 2026

16-04-2026

Stephen J. Garry & Associates, LLC disclosed $124348636 in total holdings across 51 positions in its 13F-HR filing for the period ending March 31, 2026. The portfolio features significant allocations to ETFs including Vanguard Index Fds Growth ETF ($22617423 or 18% of total), iShares Gold Tr ($14115121), and Vanguard Bd Index Fds Total Bnd Mrkt ($10293312), alongside stocks like Apple Inc and Nvidia Corporation. All positions are held solely with no shared voting authority, put, or call options reported.

• ·All holdings reported with sole voting authority and zero shared, put, or call positions.
• ·Firm address: 990 Stewart Avenue, Suite 190, Garden City, NY 11530.

16-04-2026

JVL Associates LLC filed its 13F-HR disclosing 63 equity positions totaling $298,269,583 as of March 31, 2026, with heavy weighting in broad-market ETFs such as iShares Core S&P Total U.S. Stock Market ETF ($50.9M) and Vanguard Total Stock Market ETF ($46.1M). Individual stock holdings include Apple Inc. ($12.0M, +162 shares QoQ) and NVIDIA ($2.4M, +249 shares QoQ), reflecting minor buying activity. However, many positions, particularly ETFs like Invesco QQQ Trust ($15.4M) and Vanguard Mid-Cap ETF ($15.2M), remained flat quarter-over-quarter with no changes.

• ·No share sales reported across any positions (all sold columns = 0)
• ·Largest share increase: NVIDIA (+249 shares)
• ·Portfolio heavily tilted toward ETFs (e.g., Vanguard and iShares funds comprise significant portion of total value)
• ·Mercantile Bank Corp. holding: 65,508 shares ($3.3M), unchanged

16-04-2026

Achieve Life Sciences announced a private placement of securities for gross proceeds up to $354 million, including $180 million upfront and up to an additional $174 million from milestone-driven warrants exercisable post-FDA approval of cytisinicline. The transaction is led by Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, Paradigm BioCapital Advisors, and Marshall Wace, with participation from other investors. In connection, Andrew D. Goldberg, MD was appointed CEO and board member effective post-closing, with Richard Stewart transitioning to board director; proceeds will fund a Phase 3 trial for cytisinicline in e-cigarette cessation, commercialization, and general purposes.

• ·Private placement closing expected April 17, 2026, subject to customary conditions
• ·FDA PDUFA date for cytisinicline NDA: June 20, 2026
• ·NDA submitted June 2025, accepted September 2025
• ·Accompanying warrants expire on the later of 20th business day post-FDA approval announcement or company notice date

16-04-2026

Allegheny Financial Group filed its 13F-HR on April 16, 2026, disclosing 290 equity securities holdings totaling $741,827,472 as of March 31, 2026. Largest positions include Putnam ETF Trust Focused Large Cap ($105,879,037), Diamond Hill Funds Large Cap Concentrated ($38,304,800), and JP Morgan Exchange Traded F Flexible Debt ET ($34,663,340), alongside stocks like Exxon Mobil Corp ($21,396,144) and Apple Inc ($19,635,531). No prior period data is provided in the filing for comparison.

• ·Business address: 811 Camp Horne Road Suite 100, Pittsburgh, PA 15237
• ·All holdings reported as sole discretionary with zero shared, other manager, or performance row values
• ·SEC file number: 028-20665; CIK: 0001844148

16-04-2026

JPMorgan Chase & Co. and its wholly owned subsidiary JPMorgan Chase Financial Company LLC filed an amended shelf registration statement (S-3/A) on April 16, 2026, enabling them to offer and sell various securities, including debt securities, warrants, units, and purchase contracts, from time to time via prospectus supplements. As of December 31, 2025, JPMorgan Chase & Co. had $4.4 trillion in assets and $362.4 billion in stockholders’ equity. Net proceeds will be used for general corporate purposes, such as investments in subsidiaries, dividends, extensions of credit, hedging, or financing acquisitions and business expansion.

• ·Incorporates by reference Annual Report on Form 10-K for year ended December 31, 2025; Current Reports on Form 8-K filed January 13, 2026 (twice on January 22), February 5, 2026, and April 14, 2026; Definitive Proxy Statement on Schedule 14A filed April 6, 2026.
• ·Securities issued by JPMorgan Financial will be fully and unconditionally guaranteed by JPMorgan Chase & Co.
• ·Principal executive office: 270 Park Avenue, New York, New York 10017; Telephone: (212) 270-6000.

16-04-2026

Revolution Medicines, Inc. completed an equity offering on April 16, 2026, issuing 10,563,381 shares of common stock at $142.00 per share, plus an additional 1,584,506 shares from the underwriters' fully exercised 30-day option, with net proceeds of approximately $1,650.4 million. Concurrently, the company entered into an agreement on April 14, 2026, for a $500 million aggregate principal amount of 0.50% Convertible Senior Notes due 2033, expected to close on April 17, 2026. No declines or flat metrics were reported in this capital raise announcement.

• ·Equity Underwriting Agreement dated April 14, 2026, filed as Exhibit 1.1
• ·Automatic shelf registration statement File No. 333-277640 filed March 4, 2024
• ·Final prospectus supplement filed April 15, 2026
• ·Convertible Note Offering subject to customary closing conditions on April 17, 2026
• ·Company address: 700 Saginaw Drive, Redwood City, California 94063

16-04-2026

Grupo Financiero Galicia SA (GGAL) reported a sharp deterioration in net cash generated by operating activities for the year ended December 31, 2025, swinging to an outflow of 1,605,422 million Pesos from an inflow of 4,607,866 million Pesos in 2024, driven by net increases in loans to the non-financial private sector (10,904,408 million Pesos outflow) despite growth in private sector deposits (3,089,301 million Pesos inflow). Net cash from financing activities improved to 873,798 million Pesos from 543,987 million Pesos, contributing to a net increase in cash and cash equivalents of 2,824,742 million Pesos (down from 7,909,750 million Pesos YoY), with cash and equivalents ending at 10,272,444 million Pesos. Shareholders’ equity attributable to GFG declined slightly to 7,759,336 million Pesos from 7,954,698 million Pesos, representing 16.99% of total assets (down from 18.60%).

• ·Loan provisions: 2,947,227 million Pesos in 2025 (up from 1,135,002 million in 2024)
• ·Net loans to non-financial private sector: outflow of 10,904,408 million Pesos in 2025
• ·Deposits from non-financial private sector: inflow of 3,089,301 million Pesos in 2025 (down from 7,985,401 million in 2024)
• ·Total liquidity: 13,783,058 million Pesos as of Dec 31, 2025
• ·Total loans private sector: 26,055,556 million Pesos as of Dec 31, 2025
• ·Tangible Shareholders’ Equity % of Total Assets: 16.16% in 2025 (down from 17.67% in 2024)

16-04-2026

South Plains Financial, Inc. declared a quarterly cash dividend of $0.17 per share on its outstanding common stock. The dividend is payable on May 11, 2026, to shareholders of record as of the close of business on April 27, 2026. This announcement was made via press release on April 16, 2026.

• ·Filed under Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits)
• ·Press release attached as Exhibit 99.1

16-04-2026

Scilex Holding Co filed an S-3 shelf registration statement on April 16, 2026, to potentially issue securities for working capital, general corporate purposes, R&D, clinical trials, acquisitions, and debt repayment. The company authorizes 740,000,000 shares of Common Stock and 45,000,000 shares of Preferred Stock, with 8,491,267 Common shares and 29,057,097 Series A Preferred shares outstanding as of January 31, 2026. Forward-looking statements highlight risks including financing needs, regulatory approvals, competition, and a new cryptocurrency treasury strategy.

• ·Par value of preferred stock: $0.0001 per share
• ·Series A Certificate of Designations filed November 10, 2022
• ·Risks reference Annual Report 10-K for year ended December 31, 2024, and 10-Qs for quarters ended March 31, 2025, June 30, 2025, and September 30, 2025

16-04-2026

Alamar Biosciences, Inc. filed an S-1MEF registration statement on April 16, 2026, pursuant to Rule 462(b), to increase the number of common shares offered under its earlier effective S-1 (File No. 333-294697, originally filed March 27, 2026) by 2,156,250 shares, including 281,250 shares subject to the underwriters' option to purchase additional shares. The additional shares represent no more than 20% of the maximum aggregate offering price from the earlier statement, with contents incorporated by reference. This procedural upsizing typically indicates strong investor demand ahead of the IPO.

• ·Registrant is a Delaware corporation (I.R.S. No. 36-4899036) with principal offices at 47071 Bayside Parkway, Fremont, California 94538.
• ·Earlier S-1 (File No. 333-294697) declared effective on April 16, 2026.
• ·Company qualifies as a non-accelerated filer, smaller reporting company, and emerging growth company.

16-04-2026

Skye Bioscience, Inc. (SKYE) filed a DEFA14A Definitive Additional Proxy Materials on April 16, 2026, marked as soliciting material pursuant to §240.14a-12. The filing indicates no fee was required. No specific proposals, financial data, or other substantive details are provided in the document header.

16-04-2026

Prime Medicine, Inc. appointed Svetlana Makhni, age 42, as Chief Financial Officer and principal financial officer effective April 16, 2026, following Board approval on April 7, 2026. Ms. Makhni brings over 20 years of experience, including prior CFO roles at Marengo Therapeutics (June 2022-April 2026) and Escient Pharmaceuticals (May 2021-June 2022), as well as investment banking at BMO Capital Markets, Goldman Sachs, and others. Allan Reine, M.D. will step down as principal financial officer effective April 16, 2026, but continue as Chief Executive Officer and principal executive officer.

• ·Employment agreement includes severance of 9 months base salary plus 0.75x target bonus (or 12 months base plus 1.0x target bonus post-change in control), COBRA premium support for up to 12 months, and accelerated vesting of time-based equity post-CIC.
• ·800,000-share option vests 25% after one year then monthly over 36 months; 100,000-share option vests on milestones.
• ·Ms. Makhni holds M.B.A. from Harvard Business School and B.S. from Wharton School.
• ·No family relationships or material transactions involving Ms. Makhni.

16-04-2026

Founders Financial Securities LLC filed a 13F-HR disclosing 498 equity positions totaling $1,657,440,904 as of March 31, 2026. The portfolio is diversified across individual stocks like Alphabet Inc. (Class A: $8,029,550; Class C: $1,006,798), Broadcom Inc. ($8,099,297), and large ETF holdings such as Dimensional ETF Trust Emerging Markets Core Equity ($50,102,283). No prior period comparisons or performance metrics are provided in the filing.

• ·Filing submitted on April 16, 2026, for quarter ended March 31, 2026
• ·Investment discretion primarily SOLE or DFND across holdings
• ·Address: 1026 Cromwell Bridge Road, Suite 100, Towson, MD 21286

16-04-2026

Pulse Biosciences, Inc. posted an updated investor presentation on its website on April 16, 2026, disclosing new details about its pivotal clinical study of the nsPFA Cardiac Catheter for treating atrial fibrillation, a description of the next generation nPulse cardiac catheter under development, and a summary of 2026 corporate goals in electrophysiology, cardiac surgery, and soft tissue ablation. The Investor Deck is attached as Exhibit 99.1 and available at www.pulsebiosciences.com under 'Investors', and may be used in presentations to investors and analysts. It contains forward-looking statements subject to risks and uncertainties, and is not deemed 'filed' under the Exchange Act.

16-04-2026

McClarren Financial Advisors, Inc. filed its 13F-HR report disclosing equity holdings totaling $168878835 as of March 31, 2026, across 79 positions, all held on a sole discretionary basis. The portfolio is dominated by ETFs including Vanguard Total Stock Market ETF ($18696628), Vanguard Ultra-Short-Term Bond ETF ($15423130), and various iShares and other index funds, with individual stocks like Apple Inc. ($5263395) comprising a smaller portion. No changes in ownership style or other voting authority categories were reported.

• ·Filing date: April 16, 2026
• ·Report period end date: March 31, 2026
• ·Business address: 1364 S. Atherton Street, State College, PA 16801
• ·Phone: 814-235-1940
• ·SEC file number: 028-20497

16-04-2026

Financial Designs Corp filed its 13F-HR on April 16, 2026, reporting 40 equity holdings totaling $179648493 as of March 31, 2026. The portfolio is diversified across ETFs (e.g., iShares Core S&P Total U.S. Stock ETF at $40485585, iShares Core U.S. Aggregate Bond ETF at $27103589), technology stocks (e.g., NVIDIA at $790843, Apple at $776808), and crypto-related funds (e.g., Fidelity Wise Origin Bitcoin Fund at $1783237). No period-over-period changes are disclosed in this filing.

• ·All holdings reported as sole discretionary with zero shared voting or investment discretion.
• ·Period end date: March 31, 2026
• ·Filer CIK: 0001561383, SEC file number: 028-23192

16-04-2026

Westmount Partners, LLC reported $406,263,421 in 13F securities across 264 holdings as of March 31, 2026, in its 13F-HR filing submitted on April 16, 2026. The portfolio is concentrated in large-cap technology stocks, with top positions in Apple Inc. ($43,838,017; 172,733 shares), NVIDIA Corporation ($15,617,111; 89,548 shares), and Microsoft Corp. ($14,060,356; 37,984 shares). Other notable holdings include Amazon.com Inc. ($9,995,496) and Alphabet Inc. Class A ($9,421,835), alongside significant ETF exposures from Dimensional and iShares.

• ·Filing date: April 16, 2026
• ·Report period end: March 31, 2026
• ·Business address: 2049 Century Park East, Suite 2500, Los Angeles, CA 90067
• ·SEC file number: 028-24542

16-04-2026

Future Financial Wealth Management LLC filed a 13F-HR on April 16, 2026, disclosing total holdings of $155,172,002 across 128 positions as of March 31, 2026, primarily in ETFs and equities held on a sole basis. Top positions include Invesco Nasdaq 100 ETF ($16,956,229), Vanguard S&P 500 ETF ($16,909,250), and Capital Group Dividend Value ETF ($6,506,766). No changes in holdings were reported from the prior quarter.

• ·All positions held as sole discretionary with no reported additions, deletions, or changes
• ·Business address: 7817 Cooper Road, Ste. D, Cincinnati, OH 45242
• ·CIK: 0001801892

16-04-2026

Solitude Financial Services, an institutional investment manager, filed its 13F-HR report disclosing 39 equity holdings totaling $338,142,370 as of March 31, 2026. The portfolio is diversified across individual stocks like Berkshire Hathaway Inc ($59,348,483), Apple Inc ($5,199,934), and ETFs such as SPDR S&P 500 ETF Trust ($74,983,924) and Schwab Strategic Trust Fundamental US Large Cap ($27,144,860). No period-over-period changes or performance metrics are provided in the filing.

• ·Filing date: April 16, 2026
• ·Report period end: March 31, 2026
• ·Company address: 236 E High Street, Charlottesville, VA 22902
• ·All positions reported as sole voting/dispositive power (SH SOLE)

16-04-2026

Poinciana Advisors Group, LLC filed a 13F-HR report disclosing 130 equity positions totaling $126707494 as of March 31, 2026. The portfolio is diversified across individual stocks and ETFs, with the largest holdings in American Century ETF TR US SML CP VALU ($15775068), Vanguard Scottsdale Fds Inter Term Treas ($8856228), and Dimensional ETF Trust US Core Equity 2 ($8807472). No period-over-period changes are discernible from this single filing.

• ·Filed on April 16, 2026 for period ending March 31, 2026
• ·All positions reported as sole voting authority
• ·Address: 3300 PGA Boulevard Suite 200, Palm Beach Gardens, FL 33410

16-04-2026

Phillips Financial Management, LLC filed a 13F-HR on April 16, 2026, disclosing 283 equity holdings totaling $1,378,842,627,000 as of March 31, 2026, all held with sole investment discretion and voting authority. The portfolio features massive positions in broad market ETFs such as iShares Core S&P 500 ETF ($145,236,102,000) and Dimensional ETFs like US Targeted Value ETF ($47,325,475,000), alongside individual stocks including Apple Inc., NVIDIA Corporation, and JPMorgan Chase & Co. No changes or performance metrics relative to prior periods are provided in the filing.

• ·All 283 holdings managed with sole discretion (SH SOLE); no shared voting authority, puts, or calls reported.
• ·Heavy allocation to passive ETFs from Dimensional (e.g., intl core equity: 92,781,584 x $1,000 = $92.8B), iShares (multiple core/total market), and Schwab.
• ·Individual stock examples: NVIDIA Corporation 4,101,676 x $1,000 = $4.1B value, 23,519 shares; Microsoft Corp 2,918,609 x $1,000 = $2.92B, 7,885 shares.

16-04-2026

BridgePort Financial Solutions, LLC filed its 13F-HR on April 16, 2026, disclosing total holdings of $352786301 across 231 positions as of March 31, 2026. The portfolio is diversified with significant allocations to ETFs such as iShares Core S&P 500 ETF (value $30570922), Putnam Focused Large Cap ETF (value $17540715), and JPMorgan Core Plus Bond ETF (value $16236885), alongside individual stocks like Apple Inc. (value $11508796). No prior period data is provided in the filing for comparison.

• ·Filing period end date: March 31, 2026
• ·Filer address: 1776 Pleasant Plain Rd, Fairfield, IA 52556
• ·All holdings reported as sole discretionary with no shared, other manager, or performance row voting authority

16-04-2026

Vested Financial Planning, LLC filed its 13F-HR report on April 16, 2026, disclosing 27 equity positions held as of March 31, 2026, with a total market value of $131,251,788. The portfolio is heavily weighted toward Dimensional ETF Trust products, including US Core Equity 2 (980,912 shares) and World ex US Core Equity (550,554 shares), alongside positions in Apple Inc (9,652 shares), Vanguard funds, iShares ETFs, and SPDR funds. No changes in holdings or performance metrics were reported in this snapshot filing.

• ·All positions held with sole voting and investment discretion (SH SOLE); no shared or other discretion reported.
• ·Largest positions in Dimensional ETFs: US Core Equity 2 (980912 shares), World ex US Core (550554 shares), National Municipal Bond ETF (202623 shares).
• ·Smallest positions include Airbnb (2143 shares), Invesco QQQ (1050 shares), Vanguard Info Tech ETF (461 shares).

16-04-2026

Friday Financial, an investment advisor based in Dubuque, IA, filed its 13F-HR report on April 16, 2026, for the quarter ended March 31, 2026, disclosing holdings in 93 equity positions with a total market value of $290204962. All positions are held solely on a discretionary basis with no shared or other ownership reported. Top holdings by market value include iShares Core S&P Total Stock Market ETF at $66173590 (464604 shares), Schwab Strategic Trust US Large-Cap Growth ETF at $18351622 (629990 shares), and Vanguard Scottsdale Funds Intermediate-Term Treasury ETF at $13339384 (224003 shares).

• ·Holdings include major individual stocks such as Apple Inc (18241 shares, $4629337), Microsoft Corp (944 shares, $349297), and NVIDIA Corporation (4720 shares, $823231).
• ·Significant ETF allocations to Dimensional ETF Trust products, including US High Profitability ($3582156, 97447 shares) and Emerging Markets Core Equity ($9331325, 270082 shares).
• ·Portfolio diversified across US equities, international ETFs, municipal bonds, and treasuries.

16-04-2026

TOTH Financial Advisory Corp disclosed $910,961,489 in total 13F holdings across 918 positions as of March 31, 2026, in its quarterly 13F-HR filing. The portfolio expanded with significant share increases in key holdings including Alphabet Inc. Class A (+18.7% to 82,121 shares), Apple Inc. (+18.6% to 86,477 shares), and Cisco Systems Inc. (+24.5% to 211,432 shares), alongside numerous new positions like Aercap Holdings NV (1,000 shares) and many unchanged holdings such as AES Corp (7,600 shares). No share reductions were reported.

• ·Filing date: April 16, 2026
• ·Report period end: March 31, 2026
• ·Business address: 608 South King Street, Suite 300, Leesburg, VA 20175
• ·Fiscal year end: December 31
• ·No share reductions reported across the portfolio

16-04-2026

GEN Financial Management, INC. (CIK 0002032497) filed its 13F-HR on April 16, 2026, reporting holdings as of March 31, 2026, with a total portfolio market value of $161,532,639 across 51 positions, primarily ETFs from Dimensional, Vanguard, iShares, and SPDR, alongside stocks like Apple, Microsoft, Alphabet, Amazon, Berkshire Hathaway, Broadcom, Chevron, and Honeywell. The firm increased shares in several holdings, such as iShares Core 60/40 Balanced ETF (+20.5% to 4,587 shares), Microsoft (+6.5% to 1,646 shares), and Schwab US Large Cap ETF (+1.2% to 931,113 shares), while the majority of positions remained unchanged with no reported reductions. Adjustments reflect modest portfolio rebalancing toward large-cap and balanced ETFs.

• ·All holdings reported under sole voting and discretion (SH SOLE).
• ·Portfolio heavily weighted toward ETFs (e.g., Dimensional, Vanguard, iShares representing majority of top values).
• ·No changes in voting authority or discretion columns (all 0).